Porvenir · Marketing for Pharmaceutical & Biotech Companies
Poor Email Open and Click Rates
for
Pharmaceutical & Biotech Companies.
You're sending emails. Almost nobody is opening or clicking through.
Fixed for pharmaceutical & biotech companies. Pharmaceutical and biotech companies must build scientific credibility and investor confidence simultaneously.
Signs pharmaceutical & biotech companies recognise
Does this sound
familiar?
Why this hits pharmaceutical & biotech companies hardest
Sector-specific
pressure points.
Brand not communicating scientific rigour and clinical credibility to investors and KOLs
No digital strategy for building awareness with HCPs before a product launch
Website failing to explain complex mechanism-of-action in terms stakeholders understand
No content strategy building authority in a competitive therapeutic area
Our approach
How we fix it
for pharmaceutical & biotech companies.
Deliverability & List Audit
We check sender reputation, authentication setup, and list health, since a deliverability problem masks any content fix you make.
Segmentation Fix
We rebuild segmentation so emails go to the right subscribers with relevant content, rather than one blast to everyone.
Content & Subject Line Testing
We test subject lines, send times, and content formats systematically rather than guessing what works.
Track & Iterate
We monitor open, click, and unsubscribe rates over time and keep refining based on what the data shows.
What pharmaceutical & biotech companies gain
Real outcomes.
Improved email deliverability and sender reputation
Higher open and click-through rates from better-segmented sends
A repeatable testing process for ongoing improvement
FAQ
Common questions.
Do you specifically fix poor email open and click rates for pharmaceutical & biotech companies?
Yes. We understand the specific commercial context pharmaceutical & biotech companies operate in, and we apply that context directly to how we fix poor email open and click rates.
What causes poor email open and click rates for a pharmaceutical & biotech?
An unengaged or poorly segmented list being emailed as one audience These issues tend to compound for pharmaceutical & biotech companies because of brand not communicating scientific rigour and clinical credibility to investors and kols.
How quickly can you fix poor email open and click rates for our pharmaceutical & biotech?
Most engagements addressing poor email open and click rates for pharmaceutical & biotech companies show measurable movement within 30–60 days, with the full fix delivered over 4–10 weeks depending on scope.
What results should a pharmaceutical & biotech expect?
Improved email deliverability and sender reputation Higher open and click-through rates from better-segmented sends
Do you work with pharmaceutical & biotech companies outside our home market?
Yes - we work with pharmaceutical & biotech companies across North America, the UK, UAE, Europe, and Asia Pacific, delivered fully remotely.
Explore more
Related pages.
Other Problems We Solve for Pharmaceutical & Biotech Companies
- Poor Lead Quality for Pharmaceutical & Biotech Companies
- Low Social Media Engagement for Pharmaceutical & Biotech Companies
- Competitors Outranking Us in Paid Ads for Pharmaceutical & Biotech Companies
- Can't Prove Marketing ROI for Pharmaceutical & Biotech Companies
- Social Media Gets Likes But No Sales for Pharmaceutical & Biotech Companies
Poor Email Open and Click Rates for Pharmaceutical & Biotech Companies
Ready to fix
this for your pharmaceutical & biotech?
Book a discovery call. No pitch, no pressure - just a focused conversation about where you are and where you want to be.